Do investigational MET inhibitors have potential for the treatment of gastric cancer?

被引：2
|
作者：
Athauda, Avani [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Downs Rd, Sutton, Surrey, England
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2019年 / 28卷 / 04期
关键词：
MET; gastric cancer; biomarkers; receptor tyrosine kinase MET; GENE COPY NUMBER; DOUBLE-BLIND; AMPLIFICATION; ADENOCARCINOMA; RESISTANCE; EXPRESSION; SURVIVAL; THERAPY; CAPECITABINE; COMBINATION;
D O I：
10.1080/13543784.2019.1582641
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：299 / 302
页数：4
相关论文
共 50 条
  • [1] Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    Kim, Chang Gon
    Cho, Byoung Chul
    Lim, Sun Min
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 709 - 711
  • [2] Advances in MET tyrosine kinase inhibitors in gastric cancer
    Yifan Zhang
    Lin Shen
    Zhi Peng
    Cancer Biology & Medicine, 2024, 21 (06) : 484 - 498
  • [3] Advances in MET tyrosine kinase inhibitors in gastric cancer
    Yifan Zhang
    Lin Shen
    Zhi Peng
    Cancer Biology & Medicine, 2024, (06) : 484 - 498
  • [4] Advances in MET tyrosine kinase inhibitors in gastric cancer
    Zhang, Yifan
    Shen, Lin
    Peng, Zhi
    CANCER BIOLOGY & MEDICINE, 2024, 21 (06) : 484 - 498
  • [5] What potential do heterobivalent inhibitors have for the treatment of severe allergic reactions?
    Handlogten, Michael W.
    Serezani, Ana P.
    Kaplan, Mark H.
    Bilgicer, Basar
    IMMUNOTHERAPY, 2014, 6 (03) : 223 - 225
  • [6] Do STAT3 inhibitors have potential in the future for cancer therapy?
    Wong, Andrea L. A.
    Hirpara, Jayshree L.
    Pervaiz, Shazib
    Eu, Jie-Qing
    Sethi, Gautam
    Goh, Boon-Cher
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (08) : 883 - 887
  • [7] Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer
    Jaeger, Tarkan
    Ocker, Matthias
    Kiesslich, Tobias
    Neureiter, Elen
    Neureiter, Daniel
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (02) : 133 - 136
  • [8] Mechanisms of resistance to MET inhibitors in MET-amplified gastric cancer cells
    Qi, Jie
    Rogers, Andrew
    Christensen, James
    Janne, Pasi
    Engelman, Jeffrey
    CANCER RESEARCH, 2009, 69
  • [9] The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
    Parikh, Rahul A.
    Wang, Peng
    Beumer, Jan H.
    Chu, Edward
    Appleman, Leonard J.
    ONCOTARGETS AND THERAPY, 2014, 7 : 969 - 983
  • [10] MET amplification as a potential therapeutic target in gastric cancer
    Kawakami, Hisato
    Okamoto, Isamu
    Arao, Tokuzo
    Okamoto, Wataru
    Matsumoto, Kazuko
    Taniguchi, Hirokazu
    Kuwata, Kiyoko
    Yamaguchi, Haruka
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Yamada, Yasuhide
    ONCOTARGET, 2013, 4 (01) : 9 - 17
12345